Skip to content Skip to footer
Subscribe Now
Diagnostic Top 20 2024
TOP 20

Top 20 Diagnostic Companies of 2024 

Shots:   Propelled by unceasing innovations and inch-perfect precision, the diagnostic industry is advancing at an astonishing pace  In 2023, the global diagnostic test market size was valued at $210.58B and is envisioned to reach $284.38B by 2033, registering a CAGR of 3.05 percent from 2024 to 2033. Roche reclaims its first position with a revenue…
May 23, 2024

Read more

Disease of the Month – Sjögren’s Syndrome
INSIGHTS+

Disease of the Month – Sjögren’s Syndrome

Shots:  A rare autoimmune condition, Sjögren’s Syndrome is characterized by dry mouth and eye. The condition affects 0.5 to 1% of the global population of which 90% of patients are women  In this reprise of our Disease of the Month report, we bring an illuminating account of Sjögren’s Syndrome with deep dive analysis of epidemiology, market size, disease management, available therapies, patient…
May 16, 2024

Read more

PharmaShots Magazine - May 2024 Edition
MAGAZINE

PharmaShots Magazine – May 2024 Edition

Throughout April PharmaShots was swamped with the heavy traffic of life science updates. As an official media partner to Reuters Events, PharmaShots was present in Barcelona, covering groundbreaking presentations from leading biopharma companies.  Our most-read top 20 section featured reports on Top 20 RNAi Therapeutic Companies, Top 20 Biopharma Deal Terminations of 2023, and Top 20 Biopharma Companies. For…
May 15, 2024

Read more

VIEWPOINTS_Andrew Menzies-Gow1_Michael Wechsler2_2024
VIEWPOINTS

EGPA Remission with Fasenra: Michael Wechsler and Andrew Menzies Gow in Conversation with PharmaShots

Shots:  An already established biologic treatment for SEA in the US, EU5 & Japan. Fasenra is now showing exemplary remission for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA)  Today, at PharmaShots, we have a distinguished panel of speakers shedding light on advancements under the P-III MANDARA study and the recent publication of the study…
May 15, 2024

Read more

Medical Device Top 20 2024
TOP 20

Top 20 Medical Device Companies of 2024 

Shots:   Bringing innovation and technology to healthcare, the MedTech sector is growing rapidly and transforming the ways diagnosis and treatment are received  With a global market size of $503.2B in 2023, the MedTech sector anticipates reaching $776.4B by 2033 with a CAGR of 4.4 percent. With a staggering revenue of $32.31B, Medtronic ranks first in…
May 9, 2024

Read more

VIEWPOINTS_Meri Beckwith _2024
VIEWPOINTS

Infusing AI in Clinical Trials: Meri Beckwith from Lindus Health in Conversation with PharmaShots

Shots:  Meri Beckwith, Co-Founder of Lindus Health engages in a striking conversation with PharmaShots  Meri talks about bridging the gaps of clinical trials in CNS/Neurology by leveraging LLMs that are trained on nearly a million clinical trial protocols and simple machine learning models to monitor real-time clinical trial data  Meri highlights the importance of multidisciplinary…
May 8, 2024

Read more

VIEWPOINTS_Salomé Juethner_2024
VIEWPOINTS

Takeda at AAAAI 2024: Salomé Juethner highlights P-IV Results from ENABLE and EMPOWER Studies

Shots:  At the American Academy of Allergy, Asthma, & Immunology (AAAAI), Takeda presented 9 abstracts focusing on health equity and real-world data from P-IV (ENABLE) & (EMPOWER) studies evaluating HAE patients  Salomé Juethner, Senior Medical Director-Head of Rare Genetics at Takeda, in a stimulating conversation with PharmaShots, talks about shares insights from the real-world P-IV…
May 6, 2024

Read more

Insights+ Key Biosimilars Events of April 2024
INSIGHTS+

Insights+ Key Biosimilars Events of April 2024

Shots:    Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency     Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients     During April, Samsung Bioepis and Sandoz received the EC’s Marketing Authorization approval for Pyzchiva.…
May 2, 2024

Read more

RNAi Therapeutic Top 20 2024
TOP 20

Top 20 RNAi Therapeutic Companies of 2024

Shots:  RNAi therapeutics are innovative medications that enable rapid identification of specific inhibitors of disease targets across a wide range of molecule classes. Several biopharma companies are investing in RNAi therapeutics extravagantly to maintain a healthy foothold in innovative medicines  In 2023, the global RNAi drug delivery market size was valued at $84.1B and is…
April 25, 2024

Read more

Load more